Progenics Pharmaceuticals Company Profile (NASDAQ:PGNX)

About Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:PGNX
  • CUSIP: 74318710
  • Web:
  • Market Cap: $475.42 million
  • Outstanding Shares: 70,225,000
Average Prices:
  • 50 Day Moving Avg: $7.59
  • 200 Day Moving Avg: $8.91
  • 52 Week Range: $4.00 - $11.72
  • Trailing P/E Ratio: 69.79
  • Foreward P/E Ratio: 67.70
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: $69.33 million
  • Price / Sales: 6.86
  • Book Value: $1.27 per share
  • Price / Book: 5.33
  • EBIDTA: $9.25 million
  • Net Margins: 15.55%
  • Return on Equity: 12.27%
  • Return on Assets: 8.24%
  • Current Ratio: 7.71%
  • Quick Ratio: 7.71%
  • Average Volume: 1.18 million shs.
  • Beta: 3.11
  • Short Ratio: 4.17

Frequently Asked Questions for Progenics Pharmaceuticals (NASDAQ:PGNX)

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) released its quarterly earnings data on Thursday, May, 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.07. The company earned $2.40 million during the quarter, compared to analysts' expectations of $4.50 million. Progenics Pharmaceuticals had a net margin of 15.55% and a return on equity of 12.27%. Progenics Pharmaceuticals's quarterly revenue was down 4.0% on a year-over-year basis. During the same period last year, the firm earned ($0.18) earnings per share. View Progenics Pharmaceuticals' Earnings History.

When will Progenics Pharmaceuticals make its next earnings announcement?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Progenics Pharmaceuticals.

Where is Progenics Pharmaceuticals' stock going? Where will Progenics Pharmaceuticals' stock price be in 2017?

5 analysts have issued 1 year price objectives for Progenics Pharmaceuticals' shares. Their predictions range from $11.00 to $14.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $12.20 in the next twelve months. View Analyst Ratings for Progenics Pharmaceuticals.

What are analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (5/10/2017)
  • 2. Needham & Company LLC analysts commented, "We recently chose PGNX as our Top Pick for 2017 and are now going one step further and upgrading it to Strong Buy. We continue to expect significant appreciation in shares this year as the company launches its first wholly owned product and moves rapidly toward profitability. Our increased $14 price target reflects the introduction of estimates for the 1404 imaging agent, which recently passed an interim analysis in its pivotal trial." (2/6/2017)

Are investors shorting Progenics Pharmaceuticals?

Progenics Pharmaceuticals saw a decline in short interest during the month of April. As of April 28th, there was short interest totalling 7,797,274 shares, a decline of 2.3% from the April 13th total of 7,977,161 shares. Based on an average daily trading volume, of 856,888 shares, the short-interest ratio is presently 9.1 days.

Who are some of Progenics Pharmaceuticals' key competitors?

Who owns Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.57%), Vanguard Group Inc. (5.89%), FMR LLC (4.26%), Eagle Asset Management Inc. (3.79%), State Street Corp (3.70%) and Pinnacle Associates Ltd. (3.64%). Company insiders that own Progenics Pharmaceuticals stock include Healthcare Master Fun Broadfin and Robert J Israel. View Institutional Ownership Trends for Progenics Pharmaceuticals.

Who sold Progenics Pharmaceuticals stock? Who is selling Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Alliancebernstein L.P., Royce & Associates LP, Pinnacle Associates Ltd., Morgan Stanley, Searle & CO., UBS Group AG and Stifel Financial Corp. View Insider Buying and Selling for Progenics Pharmaceuticals.

Who bought Progenics Pharmaceuticals stock? Who is buying Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Park West Asset Management LLC, Goldman Sachs Group Inc., State Street Corp, Principal Financial Group Inc., Bank of New York Mellon Corp and Ameriprise Financial Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy Progenics Pharmaceuticals stock?

Shares of Progenics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Progenics Pharmaceuticals stock cost?

One share of Progenics Pharmaceuticals stock can currently be purchased for approximately $6.77.

Analyst Ratings

Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (?)
Ratings Breakdown: 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.20)
Consensus Price Target: $12.20 (80.21% upside)

Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/24/2017Needham & Company LLCReiterated RatingStrong-BuyLowView Rating Details
4/4/2017Jefferies Group LLCBoost Price TargetBuy$13.00 -> $14.00MediumView Rating Details
11/30/2016BTIG ResearchBoost Price TargetBuy$9.00 -> $11.00N/AView Rating Details
11/8/2016AegisReiterated RatingBuy$11.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$11.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Earnings History by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.16)($0.23)$4.50 million$2.40 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.20)($0.10)$4.43 million$4.65 millionViewListenView Earnings Details
11/7/2016Q316$0.55$0.52$52.90 million$53.90 millionViewListenView Earnings Details
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)
2017 EPS Consensus Estimate: ($0.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)


Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Insider Ownership Percentage: 5.48%
Institutional Ownership Percentage: 85.95%
Insider Trades by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Insider Trades by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Healthcare Master Fun BroadfinMajor ShareholderSell602,600$9.66$5,821,116.00View SEC Filing  
2/9/2017Healthcare Master Fun BroadfinMajor ShareholderSell351,300$9.71$3,411,123.00View SEC Filing  
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Progenics Pharmaceuticals (NASDAQ:PGNX)
Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateHeadline logoZacks Investment Research Lowers Progenics Pharmaceuticals, Inc. (PGNX) to Sell - May 14 at 8:58 PM logoProgenics Is Starting To Look Interesting Again - Seeking Alpha - May 12 at 8:20 AM logoProgenics Pharmaceuticals, Inc. (PGNX) Sees Significant Decrease in Short Interest - May 11 at 7:18 AM logoHaemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View - May 9 at 11:07 AM logoHenry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View - May 9 at 11:07 AM logoFY2021 EPS Estimates for Progenics Pharmaceuticals, Inc. Cut by Analyst (PGNX) - May 8 at 12:28 PM logoProgenics Pharmaceuticals, Inc. (PGNX) Posts Earnings Results, Misses Expectations By $0.07 EPS - May 5 at 11:13 PM logoEdited Transcript of PGNX earnings conference call or presentation 4-May-17 12:30pm GMT - May 5 at 8:43 AM logoProgenics reports 1Q loss - May 4 at 9:29 AM logoProgenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update - Yahoo Finance - May 4 at 8:14 AM logoInvestor Network: Progenics Pharmaceuticals, Inc. to Host Earnings Call - May 4 at 8:14 AM logoProgenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update - May 4 at 8:14 AM logoSomewhat Favorable News Coverage Somewhat Likely to Affect Progenics Pharmaceuticals (PGNX) Stock Price - May 3 at 2:12 PM logoProgenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Brokerages - May 2 at 12:42 PM logoHill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2 - May 1 at 11:39 AM logoFavorable Press Coverage Somewhat Likely to Impact Progenics Pharmaceuticals (PGNX) Stock Price - April 29 at 1:01 AM logoProgenics Pharmaceuticals Sets First Quarter 2017 Financial Results Call for May 4 - April 27 at 7:42 PM logoChemed's (CHE) Earnings and Revenues Beat Estimates in Q1 - April 27 at 10:29 AM logoETFs with exposure to Progenics Pharmaceuticals, Inc. : April 25, 2017 - April 25 at 6:21 PM logoProgenics Pharmaceuticals (PGNX) Earning Favorable Press Coverage, Analysis Shows - April 25 at 1:52 PM logoNeedham & Company LLC Reaffirms Strong-Buy Rating for Progenics Pharmaceuticals, Inc. (PGNX) - April 24 at 4:00 PM logoNeedham Warming to Progenics Pharma (PGNX) After NDR - - April 24 at 3:22 PM logoProgenics Pharmaceuticals (PGNX) Given Media Impact Score of 0.06 - April 22 at 12:59 AM logoProgenics Pharmaceuticals (PGNX) Announces Presentations at ASCO - - April 21 at 7:02 PM logoProgenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - April 20 at 7:19 PM logoProgenics Moves Ahead Towards NDA Filing For Azedra - April 19 at 7:12 PM logoProgenics Pharmaceuticals (PGNX) Given Media Sentiment Score of 0.56 - April 18 at 10:20 AM logoProgenics Pharmaceuticals (PGNX) Getting Somewhat Favorable Media Coverage, Report Finds - April 15 at 5:15 PM logoProgenics Pharmaceuticals, Inc. (PGNX) Short Interest Update - April 14 at 10:56 AM logoProgenics Pharmaceuticals (PGNX) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 11:52 AM logoProgenics Pharmaceuticals, Inc. (PGNX) Forecasted to Earn Q1 2017 Earnings of ($0.16) Per Share - April 6 at 1:34 PM logoProgenics Pharmaceuticals, Inc. (PGNX) Given Consensus Rating of "Buy" by Brokerages - April 5 at 12:25 AM logoProgenics Pharmaceuticals, Inc. (PGNX) Earns "Buy" Rating from Jefferies Group LLC - April 4 at 9:48 PM logoExclusive: Progenics CEO Talks Regulatory Climate, Positive Trials For Ultra-Orphan Azedra - April 4 at 4:37 AM logoProgenics Pharmaceuticals' (PGNX) "Strong-Buy" Rating Reiterated at Needham & Company LLC - April 2 at 7:54 PM logoProgenics Pharma (PGNX) Reports Positive Topline Phase 2b Trial Results for AZEDRA® - - March 31 at 8:44 AM logoProgenics Azedra Succeeds in Mid-Stage Trials (PGNX) - March 30 at 7:30 PM logoProgenics Pharmaceuticals (PGNX) Presents On Targeting and Treating Cancer - Slideshow - March 30 at 7:30 PM logoProgenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA® - March 30 at 7:30 PM logoPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - March 30 at 7:30 PM logoProgenics Pharmaceuticals Inc Conference Call to Discuss Topline Results from Phase 2b Trial of AZEDRA scheduled for 8:30 am ET today - March 30 at 7:30 PM logoProgenics Azedra Succeeds in Mid-Stage Trials - March 30 at 7:30 PM logoProgenics Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference - March 30 at 5:22 PM logoProgenics Pharmaceuticals, Inc. (PGNX) Sees Large Drop in Short Interest - March 27 at 7:17 AM logoProgenics Pharma (PGNX) Announces Data from Phase 2 Study of ... - - March 26 at 8:09 AM logoProgenics Pharma (PGNX) Announces Data from Phase 2 Study of PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine - March 24 at 7:04 PM logoData from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine - March 24 at 7:04 PM logo8:31 am Progenics Pharm announces the publication of previously-reported results from the Phase 2 study of 1404 in the online edition of the Journal of Nuclear Medicine - March 24 at 7:04 PM logoPROGENICS PHARMACEUTICALS INC Financials - March 15 at 7:25 PM logoJefferies Group Comments on Progenics Pharmaceuticals, Inc.’s Q1 2017 Earnings (PGNX) - March 13 at 8:23 AM



Progenics Pharmaceuticals (PGNX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff